Global Pharma Ophthalmic

Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therapeutic Class (Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}, Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}, Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}, Anti-allergy Drugs, Anti-VEGF Agents, Others), Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}, Allergy, Uveitis, Others) Players and Region - Global Market Outlook to 2026

Pharma Ophthalmic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Pharma Ophthalmic Market Overview:
Pharma ophthalmic drugs are used to treat eye-related infections and diseases. Based on disease indication the market has been segmented into glaucoma, infection, retinal disorders, and allergy, among others. Based on the therapeutic class the market has been segmented into anti-inflammatory drugs, anti-glaucoma drugs, anti-infective drugs, anti-allergy drugs, among others. Some of the drugs need prescription whereas some of them are available without prescription over the counter. Advancement in technologies and increasing R & D in pharmaceuticals are some of the key factors booming the growth of the pharma ophthalmic drugs market across the globe. Some of the players profiled in the study are Valeant Pharmaceuticals International, Inc. (United States), Pfizer Inc. (United States), Aerie Pharmaceuticals, Inc. (United States), ALLERGAN (Ireland), Shire Plc (Ireland), Genentech, Inc. (United States), Santen Pharmaceutical Co., Ltd. (Japan), Novartis AG (Switzerland), Bayer Pharma AG (Germany) and Regeneron Pharmaceuticals, Inc. (United States).

On the basis of geography, the market of Pharma Ophthalmic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Southeast Asia, Pakistan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Spain, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Nigeria, South Africa, Rest of Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Pharma Ophthalmic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Class, the sub-segment i.e. Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids} will boost the Pharma Ophthalmic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Dry Eye will boost the Pharma Ophthalmic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Prevalence Of Diabetes
  • A Rising Aging Population Along With Global Population
  • Increasing Awareness In Healthcare Spending
  • Growth Of Glaucoma And Uveitis Treatments For Unmet Needs
  • Increasing Incidences Of Eye Disorders

Influencing Trend
  • Shifting To Back Of The Eye Diseases Including Glaucomatous Optic Neuropathy

Restraints
  • Lack Of Awareness Regarding Eye Diseases
  • Disorders In Underdeveloped And Developing Countries

Opportunities
  • R&D And Product Innovation
  • Emerging Demand From Economies


Key Market Developments:


On 18 Dec. 2017, Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company has announced that the U.S. FDA has approved Rhopressa (netarsudil ophthalmic solution) 0.02 percent for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. and On 6 April 2017 Novartis has announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The concluding of the transaction is subject to customary closing conditions including regulatory approvals.

The competitive rivalry among the players is high as the leading players are constantly focusing on product innovation through R&D. The prominent players are adopting organic and inorganic strategies to cater the innovative drugs and solutions as per the market necessities. Owing to the rising demand for ophthalmic drugs across the globe, the giant players are increasing their product manufacturing capacity. The threat of new entry is expected in the range of medium to high owing to the high R&D investment, FDA approvals, and high initial investment.

Target Audience:
Pharma Ophthalmic Manufacturers, Pharma Ophthalmic Traders/Distributors, Pharma Ophthalmic Importer/Exporter, Regulatory & Government Bodies and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Pharma Ophthalmic market on the basis of product [Prescription Drugs and Over-the-Counter Drugs] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Pharma Ophthalmic market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Southeast Asia, Pakistan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Spain, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Nigeria, South Africa, Rest of Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Pharma Ophthalmic industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Pharma Ophthalmic market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription Drugs
  • Over-the-Counter Drugs
By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies & Drug Stores

By Therapeutic Class
  • Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}
  • Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}
  • Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

By Disease Indication
  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}
  • Allergy
  • Uveitis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Southeast Asia
    • Pakistan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Nigeria
    • South Africa
    • Rest of Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence Of Diabetes
      • 3.2.2. A Rising Aging Population Along With Global Population
      • 3.2.3. Increasing Awareness In Healthcare Spending
      • 3.2.4. Growth Of Glaucoma And Uveitis Treatments For Unmet Needs
      • 3.2.5. Increasing Incidences Of Eye Disorders
    • 3.3. Market Trends
      • 3.3.1. Shifting To Back Of The Eye Diseases Including Glaucomatous Optic Neuropathy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharma Ophthalmic, by Type, Distribution Channel, Therapeutic Class, Disease Indication and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pharma Ophthalmic (Value)
      • 5.2.1. Global Pharma Ophthalmic by: Type (Value)
        • 5.2.1.1. Prescription Drugs
        • 5.2.1.2. Over-the-Counter Drugs
      • 5.2.2. Global Pharma Ophthalmic by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Online Pharmacies
        • 5.2.2.3. Independent Pharmacies & Drug Stores
      • 5.2.3. Global Pharma Ophthalmic by: Therapeutic Class (Value)
        • 5.2.3.1. Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}
        • 5.2.3.2. Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}
        • 5.2.3.3. Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}
        • 5.2.3.4. Anti-allergy Drugs
        • 5.2.3.5. Anti-VEGF Agents
        • 5.2.3.6. Others
      • 5.2.4. Global Pharma Ophthalmic by: Disease Indication (Value)
        • 5.2.4.1. Dry Eye
        • 5.2.4.2. Glaucoma
        • 5.2.4.3. Infection/Inflammation
        • 5.2.4.4. Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}
        • 5.2.4.5. Allergy
        • 5.2.4.6. Uveitis
        • 5.2.4.7. Others
      • 5.2.5. Global Pharma Ophthalmic Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Southeast Asia
          • 5.2.5.2.7. Pakistan
          • 5.2.5.2.8. Australia
          • 5.2.5.2.9. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Spain
          • 5.2.5.3.4. Italy
          • 5.2.5.3.5. United Kingdom
          • 5.2.5.3.6. Netherlands
          • 5.2.5.3.7. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Nigeria
          • 5.2.5.4.3. South Africa
          • 5.2.5.4.4. Rest of Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Pharma Ophthalmic (Volume)
      • 5.3.1. Global Pharma Ophthalmic by: Type (Volume)
        • 5.3.1.1. Prescription Drugs
        • 5.3.1.2. Over-the-Counter Drugs
      • 5.3.2. Global Pharma Ophthalmic by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Online Pharmacies
        • 5.3.2.3. Independent Pharmacies & Drug Stores
      • 5.3.3. Global Pharma Ophthalmic by: Therapeutic Class (Volume)
        • 5.3.3.1. Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}
        • 5.3.3.2. Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}
        • 5.3.3.3. Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}
        • 5.3.3.4. Anti-allergy Drugs
        • 5.3.3.5. Anti-VEGF Agents
        • 5.3.3.6. Others
      • 5.3.4. Global Pharma Ophthalmic by: Disease Indication (Volume)
        • 5.3.4.1. Dry Eye
        • 5.3.4.2. Glaucoma
        • 5.3.4.3. Infection/Inflammation
        • 5.3.4.4. Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}
        • 5.3.4.5. Allergy
        • 5.3.4.6. Uveitis
        • 5.3.4.7. Others
      • 5.3.5. Global Pharma Ophthalmic Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Southeast Asia
          • 5.3.5.2.7. Pakistan
          • 5.3.5.2.8. Australia
          • 5.3.5.2.9. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Spain
          • 5.3.5.3.4. Italy
          • 5.3.5.3.5. United Kingdom
          • 5.3.5.3.6. Netherlands
          • 5.3.5.3.7. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Nigeria
          • 5.3.5.4.3. South Africa
          • 5.3.5.4.4. Rest of Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Pharma Ophthalmic (Price)
      • 5.4.1. Global Pharma Ophthalmic by: Type (Price)
  • 6. Pharma Ophthalmic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Valeant Pharmaceuticals International, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aerie Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ALLERGAN (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shire Plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Santen Pharmaceutical Co., Ltd. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer Pharma AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pharma Ophthalmic Sale, by Type, Distribution Channel, Therapeutic Class, Disease Indication and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pharma Ophthalmic (Value)
      • 7.2.1. Global Pharma Ophthalmic by: Type (Value)
        • 7.2.1.1. Prescription Drugs
        • 7.2.1.2. Over-the-Counter Drugs
      • 7.2.2. Global Pharma Ophthalmic by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Online Pharmacies
        • 7.2.2.3. Independent Pharmacies & Drug Stores
      • 7.2.3. Global Pharma Ophthalmic by: Therapeutic Class (Value)
        • 7.2.3.1. Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}
        • 7.2.3.2. Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}
        • 7.2.3.3. Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}
        • 7.2.3.4. Anti-allergy Drugs
        • 7.2.3.5. Anti-VEGF Agents
        • 7.2.3.6. Others
      • 7.2.4. Global Pharma Ophthalmic by: Disease Indication (Value)
        • 7.2.4.1. Dry Eye
        • 7.2.4.2. Glaucoma
        • 7.2.4.3. Infection/Inflammation
        • 7.2.4.4. Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}
        • 7.2.4.5. Allergy
        • 7.2.4.6. Uveitis
        • 7.2.4.7. Others
      • 7.2.5. Global Pharma Ophthalmic Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Southeast Asia
          • 7.2.5.2.7. Pakistan
          • 7.2.5.2.8. Australia
          • 7.2.5.2.9. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Spain
          • 7.2.5.3.4. Italy
          • 7.2.5.3.5. United Kingdom
          • 7.2.5.3.6. Netherlands
          • 7.2.5.3.7. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Nigeria
          • 7.2.5.4.3. South Africa
          • 7.2.5.4.4. Rest of Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Pharma Ophthalmic (Volume)
      • 7.3.1. Global Pharma Ophthalmic by: Type (Volume)
        • 7.3.1.1. Prescription Drugs
        • 7.3.1.2. Over-the-Counter Drugs
      • 7.3.2. Global Pharma Ophthalmic by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Online Pharmacies
        • 7.3.2.3. Independent Pharmacies & Drug Stores
      • 7.3.3. Global Pharma Ophthalmic by: Therapeutic Class (Volume)
        • 7.3.3.1. Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids}
        • 7.3.3.2. Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others}
        • 7.3.3.3. Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others}
        • 7.3.3.4. Anti-allergy Drugs
        • 7.3.3.5. Anti-VEGF Agents
        • 7.3.3.6. Others
      • 7.3.4. Global Pharma Ophthalmic by: Disease Indication (Volume)
        • 7.3.4.1. Dry Eye
        • 7.3.4.2. Glaucoma
        • 7.3.4.3. Infection/Inflammation
        • 7.3.4.4. Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others}
        • 7.3.4.5. Allergy
        • 7.3.4.6. Uveitis
        • 7.3.4.7. Others
      • 7.3.5. Global Pharma Ophthalmic Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Southeast Asia
          • 7.3.5.2.7. Pakistan
          • 7.3.5.2.8. Australia
          • 7.3.5.2.9. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Spain
          • 7.3.5.3.4. Italy
          • 7.3.5.3.5. United Kingdom
          • 7.3.5.3.6. Netherlands
          • 7.3.5.3.7. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Nigeria
          • 7.3.5.4.3. South Africa
          • 7.3.5.4.4. Rest of Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Pharma Ophthalmic (Price)
      • 7.4.1. Global Pharma Ophthalmic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharma Ophthalmic: by Type(USD Million)
  • Table 2. Pharma Ophthalmic Prescription Drugs , by Region USD Million (2015-2020)
  • Table 3. Pharma Ophthalmic Over-the-Counter Drugs , by Region USD Million (2015-2020)
  • Table 4. Pharma Ophthalmic: by Distribution Channel(USD Million)
  • Table 5. Pharma Ophthalmic Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Pharma Ophthalmic Online Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Pharma Ophthalmic Independent Pharmacies & Drug Stores , by Region USD Million (2015-2020)
  • Table 8. Pharma Ophthalmic: by Therapeutic Class(USD Million)
  • Table 9. Pharma Ophthalmic Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids} , by Region USD Million (2015-2020)
  • Table 10. Pharma Ophthalmic Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others} , by Region USD Million (2015-2020)
  • Table 11. Pharma Ophthalmic Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others} , by Region USD Million (2015-2020)
  • Table 12. Pharma Ophthalmic Anti-allergy Drugs , by Region USD Million (2015-2020)
  • Table 13. Pharma Ophthalmic Anti-VEGF Agents , by Region USD Million (2015-2020)
  • Table 14. Pharma Ophthalmic Others , by Region USD Million (2015-2020)
  • Table 15. Pharma Ophthalmic: by Disease Indication(USD Million)
  • Table 16. Pharma Ophthalmic Dry Eye , by Region USD Million (2015-2020)
  • Table 17. Pharma Ophthalmic Glaucoma , by Region USD Million (2015-2020)
  • Table 18. Pharma Ophthalmic Infection/Inflammation , by Region USD Million (2015-2020)
  • Table 19. Pharma Ophthalmic Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others} , by Region USD Million (2015-2020)
  • Table 20. Pharma Ophthalmic Allergy , by Region USD Million (2015-2020)
  • Table 21. Pharma Ophthalmic Uveitis , by Region USD Million (2015-2020)
  • Table 22. Pharma Ophthalmic Others , by Region USD Million (2015-2020)
  • Table 23. South America Pharma Ophthalmic, by Country USD Million (2015-2020)
  • Table 24. South America Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 25. South America Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 26. South America Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 27. South America Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 28. Brazil Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 29. Brazil Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 30. Brazil Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 31. Brazil Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 32. Argentina Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 33. Argentina Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 34. Argentina Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 35. Argentina Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 36. Rest of South America Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 38. Rest of South America Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 39. Rest of South America Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 40. Asia Pacific Pharma Ophthalmic, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 42. Asia Pacific Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 43. Asia Pacific Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 44. Asia Pacific Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 45. China Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 46. China Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 47. China Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 48. China Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 49. Japan Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 50. Japan Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 51. Japan Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 52. Japan Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 53. India Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 54. India Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 55. India Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 56. India Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 57. South Korea Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 58. South Korea Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 59. South Korea Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 60. South Korea Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 61. Taiwan Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 62. Taiwan Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 63. Taiwan Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 64. Taiwan Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 65. Southeast Asia Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 66. Southeast Asia Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 67. Southeast Asia Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 68. Southeast Asia Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 69. Pakistan Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 70. Pakistan Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 71. Pakistan Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 72. Pakistan Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 73. Australia Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 74. Australia Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 75. Australia Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 76. Australia Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 81. Europe Pharma Ophthalmic, by Country USD Million (2015-2020)
  • Table 82. Europe Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 83. Europe Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 84. Europe Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 85. Europe Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 86. Germany Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 87. Germany Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 88. Germany Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 89. Germany Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 90. France Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 91. France Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 92. France Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 93. France Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 94. Spain Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 95. Spain Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 96. Spain Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 97. Spain Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 98. Italy Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 99. Italy Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 100. Italy Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 101. Italy Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 102. United Kingdom Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 103. United Kingdom Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 104. United Kingdom Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 105. United Kingdom Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 106. Netherlands Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 107. Netherlands Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 108. Netherlands Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 109. Netherlands Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 110. Rest of Europe Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 111. Rest of Europe Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 112. Rest of Europe Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 113. Rest of Europe Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 114. MEA Pharma Ophthalmic, by Country USD Million (2015-2020)
  • Table 115. MEA Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 116. MEA Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 117. MEA Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 118. MEA Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 119. Middle East Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 120. Middle East Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 121. Middle East Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 122. Middle East Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 123. Nigeria Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 124. Nigeria Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 125. Nigeria Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 126. Nigeria Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 127. South Africa Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 128. South Africa Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 129. South Africa Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 130. South Africa Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 131. Rest of Africa Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 132. Rest of Africa Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 133. Rest of Africa Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 134. Rest of Africa Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 135. North America Pharma Ophthalmic, by Country USD Million (2015-2020)
  • Table 136. North America Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 137. North America Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 138. North America Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 139. North America Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 140. United States Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 141. United States Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 142. United States Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 143. United States Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 144. Canada Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 145. Canada Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 146. Canada Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 147. Canada Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 148. Mexico Pharma Ophthalmic, by Type USD Million (2015-2020)
  • Table 149. Mexico Pharma Ophthalmic, by Distribution Channel USD Million (2015-2020)
  • Table 150. Mexico Pharma Ophthalmic, by Therapeutic Class USD Million (2015-2020)
  • Table 151. Mexico Pharma Ophthalmic, by Disease Indication USD Million (2015-2020)
  • Table 152. Pharma Ophthalmic Sales: by Type(K Units)
  • Table 153. Pharma Ophthalmic Sales Prescription Drugs , by Region K Units (2015-2020)
  • Table 154. Pharma Ophthalmic Sales Over-the-Counter Drugs , by Region K Units (2015-2020)
  • Table 155. Pharma Ophthalmic Sales: by Distribution Channel(K Units)
  • Table 156. Pharma Ophthalmic Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 157. Pharma Ophthalmic Sales Online Pharmacies , by Region K Units (2015-2020)
  • Table 158. Pharma Ophthalmic Sales Independent Pharmacies & Drug Stores , by Region K Units (2015-2020)
  • Table 159. Pharma Ophthalmic Sales: by Therapeutic Class(K Units)
  • Table 160. Pharma Ophthalmic Sales Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids} , by Region K Units (2015-2020)
  • Table 161. Pharma Ophthalmic Sales Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others} , by Region K Units (2015-2020)
  • Table 162. Pharma Ophthalmic Sales Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others} , by Region K Units (2015-2020)
  • Table 163. Pharma Ophthalmic Sales Anti-allergy Drugs , by Region K Units (2015-2020)
  • Table 164. Pharma Ophthalmic Sales Anti-VEGF Agents , by Region K Units (2015-2020)
  • Table 165. Pharma Ophthalmic Sales Others , by Region K Units (2015-2020)
  • Table 166. Pharma Ophthalmic Sales: by Disease Indication(K Units)
  • Table 167. Pharma Ophthalmic Sales Dry Eye , by Region K Units (2015-2020)
  • Table 168. Pharma Ophthalmic Sales Glaucoma , by Region K Units (2015-2020)
  • Table 169. Pharma Ophthalmic Sales Infection/Inflammation , by Region K Units (2015-2020)
  • Table 170. Pharma Ophthalmic Sales Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others} , by Region K Units (2015-2020)
  • Table 171. Pharma Ophthalmic Sales Allergy , by Region K Units (2015-2020)
  • Table 172. Pharma Ophthalmic Sales Uveitis , by Region K Units (2015-2020)
  • Table 173. Pharma Ophthalmic Sales Others , by Region K Units (2015-2020)
  • Table 174. South America Pharma Ophthalmic Sales, by Country K Units (2015-2020)
  • Table 175. South America Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 176. South America Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. South America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 178. South America Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 179. Brazil Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 180. Brazil Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 181. Brazil Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 182. Brazil Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 183. Argentina Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 184. Argentina Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 185. Argentina Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 186. Argentina Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 187. Rest of South America Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 188. Rest of South America Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Rest of South America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 190. Rest of South America Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 191. Asia Pacific Pharma Ophthalmic Sales, by Country K Units (2015-2020)
  • Table 192. Asia Pacific Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 193. Asia Pacific Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 194. Asia Pacific Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 195. Asia Pacific Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 196. China Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 197. China Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 198. China Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 199. China Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 200. Japan Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 201. Japan Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 202. Japan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 203. Japan Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 204. India Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 205. India Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. India Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 207. India Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 208. South Korea Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 209. South Korea Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 210. South Korea Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 211. South Korea Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 212. Taiwan Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 213. Taiwan Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 214. Taiwan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 215. Taiwan Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 216. Southeast Asia Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 217. Southeast Asia Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 218. Southeast Asia Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 219. Southeast Asia Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 220. Pakistan Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 221. Pakistan Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 222. Pakistan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 223. Pakistan Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 224. Australia Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 225. Australia Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 226. Australia Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 227. Australia Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 228. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 229. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 230. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 231. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 232. Europe Pharma Ophthalmic Sales, by Country K Units (2015-2020)
  • Table 233. Europe Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 234. Europe Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. Europe Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 236. Europe Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 237. Germany Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 238. Germany Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 239. Germany Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 240. Germany Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 241. France Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 242. France Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 243. France Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 244. France Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 245. Spain Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 246. Spain Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 247. Spain Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 248. Spain Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 249. Italy Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 250. Italy Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 251. Italy Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 252. Italy Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 253. United Kingdom Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 254. United Kingdom Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 255. United Kingdom Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 256. United Kingdom Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 257. Netherlands Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 258. Netherlands Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 259. Netherlands Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 260. Netherlands Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 261. Rest of Europe Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 262. Rest of Europe Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 263. Rest of Europe Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 264. Rest of Europe Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 265. MEA Pharma Ophthalmic Sales, by Country K Units (2015-2020)
  • Table 266. MEA Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 267. MEA Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 268. MEA Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 269. MEA Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 270. Middle East Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 271. Middle East Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 272. Middle East Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 273. Middle East Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 274. Nigeria Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 275. Nigeria Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 276. Nigeria Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 277. Nigeria Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 278. South Africa Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 279. South Africa Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 280. South Africa Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 281. South Africa Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 282. Rest of Africa Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 283. Rest of Africa Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 284. Rest of Africa Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 285. Rest of Africa Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 286. North America Pharma Ophthalmic Sales, by Country K Units (2015-2020)
  • Table 287. North America Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 288. North America Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 289. North America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 290. North America Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 291. United States Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 292. United States Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 293. United States Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 294. United States Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 295. Canada Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 296. Canada Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 297. Canada Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 298. Canada Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 299. Mexico Pharma Ophthalmic Sales, by Type K Units (2015-2020)
  • Table 300. Mexico Pharma Ophthalmic Sales, by Distribution Channel K Units (2015-2020)
  • Table 301. Mexico Pharma Ophthalmic Sales, by Therapeutic Class K Units (2015-2020)
  • Table 302. Mexico Pharma Ophthalmic Sales, by Disease Indication K Units (2015-2020)
  • Table 303. Pharma Ophthalmic: by Type(USD/Units)
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Pharma Ophthalmic: by Type(USD Million)
  • Table 315. Pharma Ophthalmic Prescription Drugs , by Region USD Million (2021-2026)
  • Table 316. Pharma Ophthalmic Over-the-Counter Drugs , by Region USD Million (2021-2026)
  • Table 317. Pharma Ophthalmic: by Distribution Channel(USD Million)
  • Table 318. Pharma Ophthalmic Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 319. Pharma Ophthalmic Online Pharmacies , by Region USD Million (2021-2026)
  • Table 320. Pharma Ophthalmic Independent Pharmacies & Drug Stores , by Region USD Million (2021-2026)
  • Table 321. Pharma Ophthalmic: by Therapeutic Class(USD Million)
  • Table 322. Pharma Ophthalmic Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids} , by Region USD Million (2021-2026)
  • Table 323. Pharma Ophthalmic Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others} , by Region USD Million (2021-2026)
  • Table 324. Pharma Ophthalmic Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others} , by Region USD Million (2021-2026)
  • Table 325. Pharma Ophthalmic Anti-allergy Drugs , by Region USD Million (2021-2026)
  • Table 326. Pharma Ophthalmic Anti-VEGF Agents , by Region USD Million (2021-2026)
  • Table 327. Pharma Ophthalmic Others , by Region USD Million (2021-2026)
  • Table 328. Pharma Ophthalmic: by Disease Indication(USD Million)
  • Table 329. Pharma Ophthalmic Dry Eye , by Region USD Million (2021-2026)
  • Table 330. Pharma Ophthalmic Glaucoma , by Region USD Million (2021-2026)
  • Table 331. Pharma Ophthalmic Infection/Inflammation , by Region USD Million (2021-2026)
  • Table 332. Pharma Ophthalmic Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others} , by Region USD Million (2021-2026)
  • Table 333. Pharma Ophthalmic Allergy , by Region USD Million (2021-2026)
  • Table 334. Pharma Ophthalmic Uveitis , by Region USD Million (2021-2026)
  • Table 335. Pharma Ophthalmic Others , by Region USD Million (2021-2026)
  • Table 336. South America Pharma Ophthalmic, by Country USD Million (2021-2026)
  • Table 337. South America Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 338. South America Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 339. South America Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 340. South America Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 341. Brazil Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 342. Brazil Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 343. Brazil Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 344. Brazil Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 345. Argentina Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 346. Argentina Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 347. Argentina Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 348. Argentina Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 349. Rest of South America Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 350. Rest of South America Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 351. Rest of South America Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 352. Rest of South America Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 353. Asia Pacific Pharma Ophthalmic, by Country USD Million (2021-2026)
  • Table 354. Asia Pacific Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 355. Asia Pacific Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 356. Asia Pacific Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 357. Asia Pacific Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 358. China Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 359. China Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 360. China Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 361. China Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 362. Japan Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 363. Japan Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 364. Japan Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 365. Japan Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 366. India Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 367. India Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 368. India Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 369. India Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 370. South Korea Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 371. South Korea Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 372. South Korea Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 373. South Korea Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 374. Taiwan Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 375. Taiwan Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 376. Taiwan Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 377. Taiwan Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 378. Southeast Asia Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 379. Southeast Asia Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 380. Southeast Asia Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 381. Southeast Asia Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 382. Pakistan Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 383. Pakistan Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 384. Pakistan Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 385. Pakistan Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 386. Australia Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 387. Australia Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 388. Australia Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 389. Australia Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 390. Rest of Asia-Pacific Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 391. Rest of Asia-Pacific Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 392. Rest of Asia-Pacific Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 393. Rest of Asia-Pacific Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 394. Europe Pharma Ophthalmic, by Country USD Million (2021-2026)
  • Table 395. Europe Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 396. Europe Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 397. Europe Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 398. Europe Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 399. Germany Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 400. Germany Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 401. Germany Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 402. Germany Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 403. France Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 404. France Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 405. France Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 406. France Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 407. Spain Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 408. Spain Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 409. Spain Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 410. Spain Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 411. Italy Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 412. Italy Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 413. Italy Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 414. Italy Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 415. United Kingdom Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 416. United Kingdom Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 417. United Kingdom Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 418. United Kingdom Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 419. Netherlands Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 420. Netherlands Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 421. Netherlands Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 422. Netherlands Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 423. Rest of Europe Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 424. Rest of Europe Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 425. Rest of Europe Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 426. Rest of Europe Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 427. MEA Pharma Ophthalmic, by Country USD Million (2021-2026)
  • Table 428. MEA Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 429. MEA Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 430. MEA Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 431. MEA Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 432. Middle East Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 433. Middle East Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 434. Middle East Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 435. Middle East Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 436. Nigeria Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 437. Nigeria Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 438. Nigeria Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 439. Nigeria Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 440. South Africa Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 441. South Africa Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 442. South Africa Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 443. South Africa Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 444. Rest of Africa Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 445. Rest of Africa Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 446. Rest of Africa Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 447. Rest of Africa Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 448. North America Pharma Ophthalmic, by Country USD Million (2021-2026)
  • Table 449. North America Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 450. North America Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 451. North America Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 452. North America Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 453. United States Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 454. United States Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 455. United States Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 456. United States Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 457. Canada Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 458. Canada Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 459. Canada Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 460. Canada Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 461. Mexico Pharma Ophthalmic, by Type USD Million (2021-2026)
  • Table 462. Mexico Pharma Ophthalmic, by Distribution Channel USD Million (2021-2026)
  • Table 463. Mexico Pharma Ophthalmic, by Therapeutic Class USD Million (2021-2026)
  • Table 464. Mexico Pharma Ophthalmic, by Disease Indication USD Million (2021-2026)
  • Table 465. Pharma Ophthalmic Sales: by Type(K Units)
  • Table 466. Pharma Ophthalmic Sales Prescription Drugs , by Region K Units (2021-2026)
  • Table 467. Pharma Ophthalmic Sales Over-the-Counter Drugs , by Region K Units (2021-2026)
  • Table 468. Pharma Ophthalmic Sales: by Distribution Channel(K Units)
  • Table 469. Pharma Ophthalmic Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 470. Pharma Ophthalmic Sales Online Pharmacies , by Region K Units (2021-2026)
  • Table 471. Pharma Ophthalmic Sales Independent Pharmacies & Drug Stores , by Region K Units (2021-2026)
  • Table 472. Pharma Ophthalmic Sales: by Therapeutic Class(K Units)
  • Table 473. Pharma Ophthalmic Sales Anti-inflammatory Drugs {Nonsteroidal Anti-inflammatory Drugs, Steroids} , by Region K Units (2021-2026)
  • Table 474. Pharma Ophthalmic Sales Anti-infective Drugs {Anti-fungal Drugs, Anti-bacterial Drugs, Others} , by Region K Units (2021-2026)
  • Table 475. Pharma Ophthalmic Sales Anti-glaucoma Drugs {Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others} , by Region K Units (2021-2026)
  • Table 476. Pharma Ophthalmic Sales Anti-allergy Drugs , by Region K Units (2021-2026)
  • Table 477. Pharma Ophthalmic Sales Anti-VEGF Agents , by Region K Units (2021-2026)
  • Table 478. Pharma Ophthalmic Sales Others , by Region K Units (2021-2026)
  • Table 479. Pharma Ophthalmic Sales: by Disease Indication(K Units)
  • Table 480. Pharma Ophthalmic Sales Dry Eye , by Region K Units (2021-2026)
  • Table 481. Pharma Ophthalmic Sales Glaucoma , by Region K Units (2021-2026)
  • Table 482. Pharma Ophthalmic Sales Infection/Inflammation , by Region K Units (2021-2026)
  • Table 483. Pharma Ophthalmic Sales Retinal Disorders {Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, Others} , by Region K Units (2021-2026)
  • Table 484. Pharma Ophthalmic Sales Allergy , by Region K Units (2021-2026)
  • Table 485. Pharma Ophthalmic Sales Uveitis , by Region K Units (2021-2026)
  • Table 486. Pharma Ophthalmic Sales Others , by Region K Units (2021-2026)
  • Table 487. South America Pharma Ophthalmic Sales, by Country K Units (2021-2026)
  • Table 488. South America Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 489. South America Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. South America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 491. South America Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 492. Brazil Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 493. Brazil Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 494. Brazil Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 495. Brazil Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 496. Argentina Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 497. Argentina Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. Argentina Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 499. Argentina Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 500. Rest of South America Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 501. Rest of South America Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 502. Rest of South America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 503. Rest of South America Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 504. Asia Pacific Pharma Ophthalmic Sales, by Country K Units (2021-2026)
  • Table 505. Asia Pacific Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 506. Asia Pacific Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 507. Asia Pacific Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 508. Asia Pacific Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 509. China Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 510. China Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 511. China Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 512. China Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 513. Japan Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 514. Japan Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 515. Japan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 516. Japan Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 517. India Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 518. India Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 519. India Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 520. India Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 521. South Korea Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 522. South Korea Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 523. South Korea Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 524. South Korea Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 525. Taiwan Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 526. Taiwan Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 527. Taiwan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 528. Taiwan Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 529. Southeast Asia Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 530. Southeast Asia Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 531. Southeast Asia Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 532. Southeast Asia Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 533. Pakistan Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 534. Pakistan Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 535. Pakistan Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 536. Pakistan Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 537. Australia Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 538. Australia Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 539. Australia Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 540. Australia Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 541. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 542. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 543. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 544. Rest of Asia-Pacific Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 545. Europe Pharma Ophthalmic Sales, by Country K Units (2021-2026)
  • Table 546. Europe Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 547. Europe Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 548. Europe Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 549. Europe Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 550. Germany Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 551. Germany Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 552. Germany Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 553. Germany Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 554. France Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 555. France Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 556. France Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 557. France Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 558. Spain Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 559. Spain Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 560. Spain Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 561. Spain Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 562. Italy Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 563. Italy Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 564. Italy Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 565. Italy Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 566. United Kingdom Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 567. United Kingdom Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 568. United Kingdom Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 569. United Kingdom Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 570. Netherlands Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 571. Netherlands Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 572. Netherlands Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 573. Netherlands Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 574. Rest of Europe Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 575. Rest of Europe Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 576. Rest of Europe Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 577. Rest of Europe Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 578. MEA Pharma Ophthalmic Sales, by Country K Units (2021-2026)
  • Table 579. MEA Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 580. MEA Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 581. MEA Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 582. MEA Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 583. Middle East Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 584. Middle East Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 585. Middle East Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 586. Middle East Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 587. Nigeria Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 588. Nigeria Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 589. Nigeria Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 590. Nigeria Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 591. South Africa Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 592. South Africa Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 593. South Africa Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 594. South Africa Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 595. Rest of Africa Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 596. Rest of Africa Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 597. Rest of Africa Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 598. Rest of Africa Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 599. North America Pharma Ophthalmic Sales, by Country K Units (2021-2026)
  • Table 600. North America Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 601. North America Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 602. North America Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 603. North America Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 604. United States Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 605. United States Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 606. United States Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 607. United States Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 608. Canada Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 609. Canada Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 610. Canada Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 611. Canada Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 612. Mexico Pharma Ophthalmic Sales, by Type K Units (2021-2026)
  • Table 613. Mexico Pharma Ophthalmic Sales, by Distribution Channel K Units (2021-2026)
  • Table 614. Mexico Pharma Ophthalmic Sales, by Therapeutic Class K Units (2021-2026)
  • Table 615. Mexico Pharma Ophthalmic Sales, by Disease Indication K Units (2021-2026)
  • Table 616. Pharma Ophthalmic: by Type(USD/Units)
  • Table 617. Research Programs/Design for This Report
  • Table 618. Key Data Information from Secondary Sources
  • Table 619. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharma Ophthalmic: by Type USD Million (2015-2020)
  • Figure 5. Global Pharma Ophthalmic: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Pharma Ophthalmic: by Therapeutic Class USD Million (2015-2020)
  • Figure 7. Global Pharma Ophthalmic: by Disease Indication USD Million (2015-2020)
  • Figure 8. South America Pharma Ophthalmic Share (%), by Country
  • Figure 9. Asia Pacific Pharma Ophthalmic Share (%), by Country
  • Figure 10. Europe Pharma Ophthalmic Share (%), by Country
  • Figure 11. MEA Pharma Ophthalmic Share (%), by Country
  • Figure 12. North America Pharma Ophthalmic Share (%), by Country
  • Figure 13. Global Pharma Ophthalmic: by Type K Units (2015-2020)
  • Figure 14. Global Pharma Ophthalmic: by Distribution Channel K Units (2015-2020)
  • Figure 15. Global Pharma Ophthalmic: by Therapeutic Class K Units (2015-2020)
  • Figure 16. Global Pharma Ophthalmic: by Disease Indication K Units (2015-2020)
  • Figure 17. South America Pharma Ophthalmic Share (%), by Country
  • Figure 18. Asia Pacific Pharma Ophthalmic Share (%), by Country
  • Figure 19. Europe Pharma Ophthalmic Share (%), by Country
  • Figure 20. MEA Pharma Ophthalmic Share (%), by Country
  • Figure 21. North America Pharma Ophthalmic Share (%), by Country
  • Figure 22. Global Pharma Ophthalmic: by Type USD/Units (2015-2020)
  • Figure 23. Global Pharma Ophthalmic share by Players 2020 (%)
  • Figure 24. Global Pharma Ophthalmic share by Players (Top 3) 2020(%)
  • Figure 25. Global Pharma Ophthalmic share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Valeant Pharmaceuticals International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Valeant Pharmaceuticals International, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Aerie Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Aerie Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. ALLERGAN (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. ALLERGAN (Ireland) Revenue: by Geography 2020
  • Figure 35. Shire Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 36. Shire Plc (Ireland) Revenue: by Geography 2020
  • Figure 37. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Genentech, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Santen Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Santen Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 43. Bayer Pharma AG (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Bayer Pharma AG (Germany) Revenue: by Geography 2020
  • Figure 45. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Global Pharma Ophthalmic: by Type USD Million (2021-2026)
  • Figure 48. Global Pharma Ophthalmic: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Pharma Ophthalmic: by Therapeutic Class USD Million (2021-2026)
  • Figure 50. Global Pharma Ophthalmic: by Disease Indication USD Million (2021-2026)
  • Figure 51. South America Pharma Ophthalmic Share (%), by Country
  • Figure 52. Asia Pacific Pharma Ophthalmic Share (%), by Country
  • Figure 53. Europe Pharma Ophthalmic Share (%), by Country
  • Figure 54. MEA Pharma Ophthalmic Share (%), by Country
  • Figure 55. North America Pharma Ophthalmic Share (%), by Country
  • Figure 56. Global Pharma Ophthalmic: by Type K Units (2021-2026)
  • Figure 57. Global Pharma Ophthalmic: by Distribution Channel K Units (2021-2026)
  • Figure 58. Global Pharma Ophthalmic: by Therapeutic Class K Units (2021-2026)
  • Figure 59. Global Pharma Ophthalmic: by Disease Indication K Units (2021-2026)
  • Figure 60. South America Pharma Ophthalmic Share (%), by Country
  • Figure 61. Asia Pacific Pharma Ophthalmic Share (%), by Country
  • Figure 62. Europe Pharma Ophthalmic Share (%), by Country
  • Figure 63. MEA Pharma Ophthalmic Share (%), by Country
  • Figure 64. North America Pharma Ophthalmic Share (%), by Country
  • Figure 65. Global Pharma Ophthalmic: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Valeant Pharmaceuticals International, Inc. (United States)
  • Pfizer Inc. (United States)
  • Aerie Pharmaceuticals, Inc. (United States)
  • ALLERGAN (Ireland)
  • Shire Plc (Ireland)
  • Genentech, Inc. (United States)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Novartis AG (Switzerland)
  • Bayer Pharma AG (Germany)
  • Regeneron Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2021 205 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharma Ophthalmic Quantitative research analysis
Global Pharma Ophthalmic Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Pharma Ophthalmic Report?

Have a Query? Click Here

Other Related Reports

Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Cli...
$ 3350
Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
$ 3650
Myocardial Infarction Drugs Comprehensive Study by Type (Vasodilators {Nitrodilators, ACE Inhibitors, ARBs}, Cardiac depressant drugs {Beta Blockers}, Antiarrhythmics {Anti-thrombotics}, Thrombolytic...
$ 3650
Leiomyosarcoma Drug Comprehensive Study by Type (AL-3818, BGB-290, C-21, Others), Application (Clinic, Hospital, Others), Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted drug therapy) P...
$ 3500
Meningitis Vaccine Comprehensive Study by Type (Meningitis A+C, Meningitis ACWY135, Meningitis B), Application (Medical Care, Healthy, Hospital), Route of Administration (Intramuscular and Subcutaneo...
$ 3650
Rosuvastatin Comprehensive Study by Type (High Purity, Low Purity), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Stores), Form Type (Capsule, Tablet), Dosage (5 ...
$ 3350